• Patients
    • Patients
    • Why Brachytherapy?
    • Why Cesium Blu?
    • Treatment Areas
      • Prostate
      • Brain
      • Gynecological
      • Head & Neck
      • Lung
    • Cesium Pioneers
    • Together
      • Share Your Story
      • Local Support Groups
      • Online Support Groups
      • Terms and Abbreviations
      • Patient Videos
  • Clinicians
    • Clinicians
    • Why Cesium Blu?
    • Cesium Pioneers
    • Products
    • Research
    • Conferences & Events
  • About
    • About
      • Quality and Regulatory
    • Contact Isoray
    • News
    • Careers
    • Management Team
  • Investors
    • Investor Relations
    • SEC Filings
    • Press Releases
    • Presentations & Events
    • Investor Contact
    • FAQ
    • Governance
      • Nominations and Corporate Governance Committee
      • Compensation Committee Charter
      • Code of Ethics for Senior Leadership
      • Code of Conduct and Ethics
      • Audit Committee
Find a Doctor

Press Releases

  • Press Releases
  • Quarterly Results

Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference

January 7, 2021

Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRO

November 24, 2020

Isoray Announces First Quarter Fiscal 2021 Financial Results

November 10, 2020

Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020

November 2, 2020

Isoray, Inc. Announces Pricing of $9.5 Million Public Offering

October 20, 2020

Isoray, Inc. Announces Proposed Underwritten Public Offering

October 19, 2020

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results

September 17, 2020

Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 16, 2020

Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020

September 10, 2020

Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck Cancers

June 17, 2020

Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer

June 2, 2020

Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131

May 12, 2020
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 5

About Us

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Patients & Families

Cesium Blu
Prostate Cancer
Treatment Areas
Together Community

Doctors & Clinicians

Cesium Blu
The Data
Contact Us
Our Products

Our Company

About Us
Careers
Contact Us
Newsroom
Investors

 

Copyright © 2021 Isoray Inc.

Terms of Use        Privacy Policy

Disclosure: The physicians featured on this website may have prior or current relationships with Isoray. These relationships may include, for example: membership on Isoray’s Advisory Board; participation as a clinical investigator in research conducted on Isoray products; provision of consultation or training services; or engagement as a prospective partner in the development of new products. Many of these physicians have received or continue to receive compensation from Isoray in one form or another. The principal nature of a specific physician’s relationship is disclosed on this website adjacent to language featuring that physician.